July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Safety and efficacy of long-term ripasudil 0.4% instillation for the reduction of intraocular pressure in Japanese open-angle glaucoma patients
Author Affiliations & Notes
  • Yuko Maruyama
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan
    Ophthalmology, Kyoto First Red Cross Hospital, Kyoto, Japan
  • Yoko Ikeda
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan
    Ophthalmology, Oike-Ikeda Eye Clinic, Kyoto, Kyoto, Japan
  • Kazuhiko Mori
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan
  • Kengo Yoshii
    Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan
  • Morio Ueno
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan
  • Haruna Yoshikawa
    Ophthalmology, Kyoto Second Red Cross Hospital, Kyoto, Kyoto, Japan
  • Chie Sotozono
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan
  • Shigeru Kinoshita
    Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Yuko Maruyama, None; Yoko Ikeda, None; Kazuhiko Mori, None; Kengo Yoshii, None; Morio Ueno, None; Haruna Yoshikawa, None; Chie Sotozono, None; Shigeru Kinoshita, Kowa (F), Kowa (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2394. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuko Maruyama, Yoko Ikeda, Kazuhiko Mori, Kengo Yoshii, Morio Ueno, Haruna Yoshikawa, Chie Sotozono, Shigeru Kinoshita; Safety and efficacy of long-term ripasudil 0.4% instillation for the reduction of intraocular pressure in Japanese open-angle glaucoma patients. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2394. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Rho-kinase-inhibitor ripasudil 0.4% eye drops have recently been approved in Japan for the treatment of glaucoma. It has been reported that ripasudil eye-drop instillation is effective in glaucoma patients, however, those studies investigated the efficacy of intraocular pressure (IOP) reduction for only about 1 year. The purpose of this study was to evaluate the safety and efficacy of long-term ripasudil 0.4% eye-drop instillation for the reduction of IOP in Japanese open-angle glaucoma (OAG) patients.

Methods : This study involved 271 eyes of 271 Japanese OAG patients (145 females, 126 males; mean age: 67.0±12.4 years) newly initiated with ripasudil 0.4% eye-drop treatment at the Department of Ophthalmology, Kyoto Prefectural University of Medicine and Oike-Ikeda Eye Clinic, Kyoto, Japan from December 2014 to August 2018. In all patients, IOP data at pre treatment and at 1-, 3-, 6-, 12-, 18-, and 24-months post initiation of continued ripasudil use was obtained, and the IOP values at each time-point were then compared. Adverse events leading to discontinuation of ripasudil eye-drop use were also investigated. If data was available from both eyes, the right-eye data was used. The paired t-test was used for statistical analysis.

Results : Of the 271 patients, 146 were normal-tension glaucoma and 125 were primary OAG. The mean observational period was 9.6±7.3 months, and the mean number of anti-glaucoma eye-drops used pre initiating ripasudil treatment was 2.5±1.3. The mean IOP value at pre initiation of ripasudil was 16.0±5.5 mmHg, and at 1-, 3-, 6-, 12-, 18-, and 24-months post initiation as 14.1±5.1, 13.5±4.2, 13.2±4.2, 14.0±4.2, 13.2±3.5, 13.6±3.2 mmHg, respectively. IOP at 1-, 3-, 6-, 12-, 18-, and 24-months post ripasudil initiation was significantly reduced compared with that at pre initiation (P<0.05, paired t-test). Adverse events for discontinuation of use included blepharitis (43 cases, 15.9%), conjunctival injection (27 cases, 10.0%), allergic conjunctivitis (17 cases, 6.3%), and discontinuation of ripasudil use due to a need to undergoing surgery (34 cases, 12.5%).

Conclusions : Our findings showed that 24-month ripasudil 0.4% eye-drop instillation is both safe and effective for IOP reduction, and that blepharitis was the primary side effect leading to discontinuation of use.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×